1 / 4

Global Biosimilars Market Is Expected To Reach US$ 25.83 Bn By 2025

The Biosimilars  market was valued at US$ 3.52 Bn in 2016, and is expected to reach US$ 25.83 Bn by 2025, expanding at a CAGR of  23.1% from 2017 to 2025.<br>

david23
Download Presentation

Global Biosimilars Market Is Expected To Reach US$ 25.83 Bn By 2025

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. Global Biosimilars Market Is Expected To Reach US$ 25.83 Bn By 2025 TheBiosimilars  market was valued at US$ 3.52 Bn in 2016, and is expected to reach US$ 25.83 Bn by 2025, expanding at a CAGR of  23.1% from 2017 to 2025.

  2. Market Insights Biosimilars are the products approved in a country which has an abbreviated approval process for biologic products that refer to an originator biologic in the regulatory submission. Biosimilars possess similar clinical properties like safety, potency and purity as compared to the original biological product. The currently available biosimilars treatment segment are by product and application. The product segment comprises of recombinant non-glycosylated proteins (Insulin, Filgastrim, Somatropin) recombinant glycosylated proteins (Monoclonal antibodies, Erythropoietin) and recombinant peptides (Glucagon, Calcitonin).The application segment comprises of oncology, chronic and autoimmune disease, blood disorders, growth hormone disease and infectious disease. The key factors assisting the growth of biosimilars are the increasing prevalence of chronic disease, rising aging population, patient inclination towards reduced healthcare expenditure and government initiatives to promote biosimilars for e.g. Europe Medicines Agency (EMA) has finalized the guidelines on biosimilars with its elements described in ICH (Q5E). On the other hand, high complexities involved in the manufacturing of biosimilars and the rigorous regulatory framework governing their approval in countries around the world are hindering the market growth of biosimilars.k Browse For Full Report Visit @ http://www.credenceresearch.com/report/biosimilars-treatment-market

  3. Pipeline Analysis Pipeline of biosimilar market comprises of (recombinant non-glycosylated proteins, recombinant glycosylated proteins and recombinant peptides). Samsung Bioepis (SB4, SB2, SB5, SB9), Sandoz (GP2015, LA-EP2006, HX575), Amgen (ABP 501, ABP 980, ABP 215), Momenta (M923, M834) etc. We have estimated sales of very specific molecules based on the above mentioned type, disease prevalence, sponsor, depicted peak sales by leading market experts and other factors.

  4. Company Profiles About Us: Credence Research is a worldwide market research and counseling firm that serves driving organizations, governments, non-legislative associations, and not-for-benefits. We offer our customers some assistance with making enduring enhancements to their execution and understand their most imperative objectives. Over almost a century, we’ve manufactured a firm extraordinarily prepared to this task. Contact: Name: Chris Smith Designation: Global Sales Manager E-mail: sales@credenceresearch.com Ph: 1-800-361-8290 Web:  http://www.credenceresearch.com

More Related